Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX and Neoadjuvant Radiation for Gastric and GE Junction Cancers
NCT03279237Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2017
- Primary completion
- Sep 2018
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fluorouracil, oxaliplatin, irinotecan, folinic acid, paclitaxel and 1 more in gastroesophageal junction cancer and gastric cancer (GC), sponsored by Massachusetts General Hospital. Primary endpoint: Completion Rate of Chemotherapy in Combination With Chemoradiation at 21 weeks. Started Oct 2017; status: completed.
02
Drugs
fluorouraciloxaliplatinirinotecanfolinic acidpaclitaxel
03
Conditions
gastroesophageal junction cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT03279237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03279237.